HIF-1α inhibition reverses multidrug resistance in colon cancer cells via downregulation of MDR1/P-Glycoprotein

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Chen, Jianfang ^a   Ding, Zhenyu ^a,b   Peng, Yonghai ^a   Pan, Feng ^a   Li, Jianjun ^a   Zou, Lan ^a   Zhang, Yanling ^a   Liang, Houjie ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; FLUOROURACIL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRINOTECAN; MULTIDRUG RESISTANCE PROTEIN 1; VINCRISTINE; ANTINEOPLASTIC AGENT; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; PROTEIN BINDING; SMALL INTERFERING RNA;

ADULT; AGED; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CHEMOSENSITIVITY; CHROMATIN IMMUNOPRECIPITATION; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE SILENCING; GENE TARGETING; GENETIC CORRELATION; GENETIC TRANSFECTION; HIF 1ALPHA GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; LOVO MULTICELLULAR SPHEROID; MAJOR CLINICAL STUDY; MALE; MDR1 GENE; MULTICELLULAR SPHEROID; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; ANOXIA; COLON TUMOR; DRUG EFFECTS; DRUG RESISTANCE; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; PROMOTER REGION; RNA INTERFERENCE; TUMOR CELL LINE;

ANOXIA; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; P-GLYCOPROTEINS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC;

EID: 84902532046     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098882     Document Type: Article

References (36)

1. Desoize B, Jardillier J (2000) Multicellular resistance: a paradigm for clinical resistance? Crit Rev Oncol Hematol 36: 193-207.
2. Morin PJ (2003) Drug resistance and the microenvironment: nature and nurture. Drug Resist Updat 6: 169-172.
3. Westhoff MA, Fulda S (2009) Adhesion-mediated apoptosis resistance in cancer. Drug Resist Updat 12: 127-136.
4. Rohwer N, Cramer T(2011) Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat 14: 191-201.
5. Brown JM (2007) Tumor hypoxia in cancer therapy. Methods Enzymol 435: 297-321.
6. Liang S, Galluzzo P, Sobol A, Skucha S, Rambo B, et al. (2012) Multimodality Approaches to Treat Hypoxic Non-Small Cell Lung Cancer (NSCLC) Microenvironment. Genes Cancer 3: 141-151.
7. Ramaekers CH, van den Beucken T, Meng A, Kassam S, Thoms J, et al. (2011) Hypoxia disrupts the Fanconi anemia pathway and sensitizes cells to chemotherapy through regulation of UBE2T. Radiother Oncol 101: 190-197.
8. Owen MR, Stamper IJ, Muthana M, Richardson GW, Dobson J, et al. (2011) Mathematical modeling predicts synergistic antitumor effects of combining a macrophage-based, hypoxia-targeted gene therapy with chemotherapy. Cancer Res 71: 2826-2837.
9. Wu CP, Calcagno AM, Ambudkar SV (2008) Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol 1: 93-105.
10. He Q, Zhang G, Hou D, Leng A, Xu M, et al. (2011) Overexpression of sorcin results in multidrug resistance in gastric cancer cells with up-regulation of P-gp. Oncol Rep 25: 237-243.
11. Chen LM, Liang YJ, Ruan JW, Ding Y, Wang XW, et al. (2004) Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318. J Pharm Pharmacol 56: 1061-1066. (Pubitemid 39140063)
12. Ding Z, Yang L, Xie X, Xie F, Pan F, et al. (2010) Expression and significance of hypoxia-inducible factor-1 alpha and MDR1/P-glycoprotein in human colon carcinoma tissue and cells. J Cancer Res Clin Oncol 136: 1697-1707.
13. Oktem G, Bilir A, Selvi N, Yurtseven ME, Vatansever S, et al. (2006) Chemotherapy influences inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) activity on 3D breast cancer cell line. Oncol Res 16: 195-203. (Pubitemid 44744178)
14. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, et al. (2002) Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 62: 3387-3394. (Pubitemid 34651384)
15. Ravizza R, Molteni R, Gariboldi MB, Marras E, Perletti G, et al. (2009) Effect of HIF-1 modulation on the response of two- and three-dimensional cultures of human colon cancer cells to 5-fluorouracil. European Journal of Cancer 45: 890-898.
16. Wartenberg M, Donmez F, Ling FC, Acker H, Hescheler J, et al. (2001) Tumor-induced angiogenesis studied in confrontation cultures of multicellular tumor spheroids and embryoid bodies grown from pluripotent embryonic stem cells. FASEB J 15: 995-1005. (Pubitemid 32290787)
17. Brown JM (2000) Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today 6: 157-162.
18. Brown JM, Giaccia AJ (1998) The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58: 1408-1416. (Pubitemid 28193601)
19. Cuvillier O, Ader I, Bouquerel P, Brizuela L, Gstalder C, et al. (2013) Hypoxia, therapeutic resistance, and sphingosine 1-phosphate. Adv Cancer Res 117: 117-141.
20. Kanagasabai R, Krishnamurthy K, Druhan LJ, Ilangovan G (2011) Forced expression of heat shock protein 27 (Hsp27) reverses P-glycoprotein (ABCB1)-mediated drug efflux and MDR1 gene expression in Adriamycin-resistant human breast cancer cells. J Biol Chem 286: 33289-33300.
21. Liu L, Ning X, Sun L, Zhang H, Shi Y, et al. (2008) Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer Sci 99: 121-128. (Pubitemid 350239040)
22. Hao J, Song X, Song B, Liu Y, Wei L, et al. (2008) Effects of lentivirus-mediated HIF-1alpha knockdown on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cells. Cancer Gene Ther 15: 449-455. (Pubitemid 351822190)
23. Dong XL, Xu PF, Miao C, Fu ZY, Li QP, et al. (2012) Hypoxia decreased chemosensitivity of breast cancer cell line MCF-7 to paclitaxel through cyclin B1. Biomed Pharmacother 66: 70-75.
24. Unruh A, Ressel A, Mohamed HG, Johnson RS, Nadrowitz R, et al. (2003) The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 22: 3213-3220. (Pubitemid 36712933)
25. Brown LM, Cowen RL, Debray C, Eustace A, Erler JT, et al. (2006) Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1. Mol Pharmacol 69: 411-418. (Pubitemid 43121938)
26. Nardinocchi L, Puca R, Sacchi A, D'Orazi G (2009) Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosis. Mol Cancer 8: 1.
27. Sasabe E, Zhou X, Li D, Oku N, Yamamoto T, et al. (2007) The involvement of hypoxia-inducible factor-1alpha in the susceptibility to gamma-rays and chemotherapeutic drugs of oral squamous cell carcinoma cells. Int J Cancer 120: 268-277. (Pubitemid 44956835)
28. Sullivan R, Pare GC, Frederiksen LJ, Semenza GL, Graham CH (2008) Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity. Mol Cancer Ther 7: 1961-1973.
29. Chen M, Huang SL, Zhang XQ, Zhang B, Zhu H, et al. (2012) Reversal effects of pantoprazole on multidrug resistance in human gastric adenocarcinoma cells by down-regulating the V-ATPases/mTOR/HIF-1alpha/P-gp and MRP1 signaling pathway in vitro and in vivo. J Cell Biochem 113: 2474-2487.
30. Hussein D, Estlin EJ, Dive C, Makin GW (2006) Chronic hypoxia promotes hypoxia-inducible factor-1alpha-dependent resistance to etoposide and vincristine in neuroblastoma cells. Mol Cancer Ther 5: 2241-2250. (Pubitemid 44530461)
31. Chang Q, Qin R, Huang T, Gao J, Feng Y (2006) Effect of antisense hypoxiainducible factor 1alpha on progression, metastasis, and chemosensitivity of pancreatic cancer. Pancreas 32: 297-305.
32. Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, et al. (2003) YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 95: 516-525. (Pubitemid 36511622)
33. Sapra P, Kraft P, Pastorino F, Ribatti D, Dumble M, et al. (2011) Potent and sustained inhibition of HIF-1alpha and downstream genes by a polyethylene-glycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects. Angiogenesis 14: 245-253.
34. Kamiyama H, Takano S, Tsuboi K, Matsumura A (2005) Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells. J Cancer Res Clin Oncol 131: 205-213. (Pubitemid 40238935)
35. Tiwari AK, Sodani K, Dai CL, Ashby CR Jr, Chen ZS (2011) Revisiting the ABCs of multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol 12: 570-594.
36. Li J, Shi M, Cao Y, Yuan W, Pang T, et al. (2006) Knockdown of hypoxiainducible factor-1alpha in breast carcinoma MCF-7 cells results in reduced tumor growth and increased sensitivity to methotrexate. Biochem Biophys Res Commun 342: 1341-1351.